WOMEN’S HEALTH APEA FINAL EXAM PREP – QUESTIONS AND
ANSWERS | VERIFIED AND WELL DETAILED ANSWERS PLUS
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE |
EXAM PREP | STUDY GUIDE | PRACTICE TEST | DOWNLOAD
INSTANT PDF
1. A 28-year-old nulliparous female presents to the clinic requesting initiation of combined
hormonal contraception (CHC). She reports a history of migraines accompanied by
transient visual field scotomas lasting approximately 20 minutes before headache onset.
According to US MEC guidelines, what is the most appropriate contraceptive
recommendation?
A. Initiate a standard low-dose combined oral contraceptive pill
B. Prescribe a progestin-only pill (mini-pill) or long-acting reversible contraception
C. Recommend a transdermal contraceptive patch containing ethinyl estradiol and norelgestromin
D. Initiate a combined vaginal ring releasing estradiol and etonogestrel
Rationale: Migraines accompanied by aura (such as visual scotomas) in women over age 35,
or even under 35, place them at a substantially increased risk of ischemic stroke when exposed
to exogenous estrogen. Per US Medical Eligibility Criteria (US MEC) for Contraceptive Use,
migraines with aura represent a Category 4 classification for CHCs, meaning the risk
outweighs any advantage. Progestin-only options or non-hormonal methods like a copper
intrauterine device are safe and appropriate alternatives.
2. A 34-year-old G2P2002 presents for routine annual gynecological examination. Her last
Pap smear three years ago was negative for intraepithelial lesion or malignancy (NILM)
with positive high-risk human papillomavirus (hrHPV) cotesting. Her current cotesting
reveals persistent hrHPV-16 positivity with a NILM cytology result. What is the standard
management guideline according to ASCCP risk-based management?
A. Repeat co-testing in exactly one year
B. Perform an immediate colposcopy with directed cervical biopsies
C. Schedule primary HPV cotesting in three years
D. Administer the 9-valent HPV vaccine series and repeat cytology in six months
Rationale: According to the American Society for Colposcopy and Cervical Pathology
(ASCCP) risk-based management guidelines, a persistent high-risk HPV genotype, specifically
HPV type 16 or 18, warrants an immediate colposcopy regardless of a negative concurrent
cytology result due to the high cumulative risk of cervical intraepithelial neoplasia grade 2 or
worse (CIN 2+).
3. A 22-year-old college student presents with a three-day history of profuse, malodorous,
yellow-green frothy vaginal discharge accompanied by moderate vulvar pruritus and
dysuria. Speculum examination reveals petechial hemorrhages scattered across the
,ectocervix, commonly referred to as a "strawberry cervix." Which diagnostic test is the
gold standard and most appropriate choice to confirm this diagnosis?
A. Affirm VPIII multiplex DNA probe assay or nucleic acid amplification test (NAAT)
B. Wet mount microscopy demonstrating clue cells with adherent bacilli
C. Culture on Thayer-Martin selective agar media
D. Potassium hydroxide (KOH) whiff test showing a strong amine odor
Rationale: The clinical presentation is classic for Trichomonas vaginalis. While wet mount
microscopy showing motile trichomonads is traditionally associated with trichomoniasis, its
sensitivity is relatively low (50 to 60 percent). Nucleic acid amplification tests (NAATs) and
molecular probe assays such as Affirm VPIII are currently considered the most sensitive and
specific diagnostic standards for detecting Trichomonas vaginalis.
4. A 42-year-old G3P3003 reports progressive, debilitating dysmenorrhea and heavy
menstrual bleeding lasting 8 days over the past year. Bimanual examination reveals a
symmetrically enlarged, globular, boggy, and moderately tender uterus. She desires uterine
preservation. What is the most likely underlying diagnosis?
A. Endometrial hyperplasia without atypia
B. Adenomyosis
C. Submucosal uterine leiomyomas
D. Chronic pelvic inflammatory disease
Rationale: Adenomyosis is characterized by the benign invasion of endometrial glands and
stroma deep into the myometrium, leading to a uniformly enlarged, boggy, and tender uterus
accompanied by heavy, painful menses. Leiomyomas (fibroids) typically present with an
irregularly enlarged, asymmetric contour rather than a smooth, symmetric, globular
enlargement.
5. A 56-year-old postmenopausal woman presents with a complaint of moderate
vulvovaginal dryness, burning, dyspareunia, and urinary urgency that has worsened over
the past 14 months since her last menstrual period. Physical examination demonstrates
pale, thin, friable vaginal mucosa with loss of rugae and fusion of the labia minora. What is
the most effective first-line medical therapy for this patient's primary condition?
A. Oral conjugated equine estrogen systemic therapy
B. Low-dose vaginal estrogen therapy (cream, tablet, or ring)
C. Systemic selective estrogen receptor modulators (SERMs)
D. High-dose oral medroxyprogesterone acetate therapy
Rationale: Genitourinary syndrome of menopause (GSM) is caused by estrogen deprivation
affecting the vulva, vagina, urethra, and bladder. Low-dose vaginal estrogen therapy provides
localized relief of symptoms with minimal systemic absorption, making it the most effective
first-line therapy for women without systemic vasomotor symptoms.
, 6. A 25-year-old nulliparous woman requests emergency contraception after experiencing a
contraceptive barrier failure (condom breakage) approximately 18 hours ago. Her body
mass index (BMI) is 34 kg/m2. Which emergency contraceptive option is the most effective
for this patient?
A. Single-dose oral levonorgestrel 1.5 mg tablet
B. Copper intrauterine device (Cu-IUD) insertion or oral ulipristal acetate
C. Combined oral contraceptive pills using the Yuzpe regimen
D. High-dose oral medroxyprogesterone acetate injection
Rationale: Levonorgestrel-based emergency contraception (Plan B) has significantly reduced
efficacy in women with a BMI over 26 kg/m2 or weight over 75 kg. Ulipristal acetate
maintains efficacy up to 88 kg, and the copper intrauterine device is highly effective regardless
of patient weight when inserted within five days of unprotected intercourse.
7. A 19-year-old female presents with lower abdominal pain and purulent cervical
discharge. Nucleic acid amplification testing (NAAT) confirms Chlamydia trachomatis
infection. In addition to treating the patient with single-dose azithromycin or doxycycline,
what critical partner management step must the clinician take?
A. Advise the patient to have partners tested only if they develop painful scrotal swelling
B. Provide expedited partner therapy (EPT) or prescriptions/referrals for all sexual partners
within the preceding 60 days
C. Require partners to obtain a mandatory pelvic ultrasound prior to receiving antibiotics
D. Instruct the patient to abstain from sexual activity for exactly 14 days post-treatment without notifying
partners
Rationale: CDC guidelines recommend treating all sexual partners within the last 60 days of a
patient diagnosed with a sexually transmitted infection like chlamydia to prevent reinfection
and community spread. Expedited partner therapy (EPT) allows clinicians to provide
medications or prescriptions directly to the patient to take to their partner without a formal
clinical evaluation, where legally permitted.
8. A 48-year-old G2P2002 presents with complaints of unpredictable menstrual cycle
intervals ranging from 22 to 45 days, accompanied by night sweats and hot flashes over the
past eight months. Her serum follicle-stimulating hormone (FSH) level is elevated at 42
IU/L. How is this clinical stage of reproductive aging classified according to STRAW+10
criteria?
A. Premenopause
B. Early menopausal transition (Stage -2)
C. Late menopausal transition (Stage -1)
D. Postmenopause (Stage +1a)
Rationale: The STRAW+10 staging system defines the late menopausal transition (Stage -1) by
persistent differences in cycle length of 7 days or more (e.g., skipped cycles or an interval of
amenorrhea of 60 days or longer). Serum FSH levels fluctuate widely during this phase and
are not diagnostic on their own, but the clinical bleeding pattern establishes the stage.
ANSWERS | VERIFIED AND WELL DETAILED ANSWERS PLUS
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE |
EXAM PREP | STUDY GUIDE | PRACTICE TEST | DOWNLOAD
INSTANT PDF
1. A 28-year-old nulliparous female presents to the clinic requesting initiation of combined
hormonal contraception (CHC). She reports a history of migraines accompanied by
transient visual field scotomas lasting approximately 20 minutes before headache onset.
According to US MEC guidelines, what is the most appropriate contraceptive
recommendation?
A. Initiate a standard low-dose combined oral contraceptive pill
B. Prescribe a progestin-only pill (mini-pill) or long-acting reversible contraception
C. Recommend a transdermal contraceptive patch containing ethinyl estradiol and norelgestromin
D. Initiate a combined vaginal ring releasing estradiol and etonogestrel
Rationale: Migraines accompanied by aura (such as visual scotomas) in women over age 35,
or even under 35, place them at a substantially increased risk of ischemic stroke when exposed
to exogenous estrogen. Per US Medical Eligibility Criteria (US MEC) for Contraceptive Use,
migraines with aura represent a Category 4 classification for CHCs, meaning the risk
outweighs any advantage. Progestin-only options or non-hormonal methods like a copper
intrauterine device are safe and appropriate alternatives.
2. A 34-year-old G2P2002 presents for routine annual gynecological examination. Her last
Pap smear three years ago was negative for intraepithelial lesion or malignancy (NILM)
with positive high-risk human papillomavirus (hrHPV) cotesting. Her current cotesting
reveals persistent hrHPV-16 positivity with a NILM cytology result. What is the standard
management guideline according to ASCCP risk-based management?
A. Repeat co-testing in exactly one year
B. Perform an immediate colposcopy with directed cervical biopsies
C. Schedule primary HPV cotesting in three years
D. Administer the 9-valent HPV vaccine series and repeat cytology in six months
Rationale: According to the American Society for Colposcopy and Cervical Pathology
(ASCCP) risk-based management guidelines, a persistent high-risk HPV genotype, specifically
HPV type 16 or 18, warrants an immediate colposcopy regardless of a negative concurrent
cytology result due to the high cumulative risk of cervical intraepithelial neoplasia grade 2 or
worse (CIN 2+).
3. A 22-year-old college student presents with a three-day history of profuse, malodorous,
yellow-green frothy vaginal discharge accompanied by moderate vulvar pruritus and
dysuria. Speculum examination reveals petechial hemorrhages scattered across the
,ectocervix, commonly referred to as a "strawberry cervix." Which diagnostic test is the
gold standard and most appropriate choice to confirm this diagnosis?
A. Affirm VPIII multiplex DNA probe assay or nucleic acid amplification test (NAAT)
B. Wet mount microscopy demonstrating clue cells with adherent bacilli
C. Culture on Thayer-Martin selective agar media
D. Potassium hydroxide (KOH) whiff test showing a strong amine odor
Rationale: The clinical presentation is classic for Trichomonas vaginalis. While wet mount
microscopy showing motile trichomonads is traditionally associated with trichomoniasis, its
sensitivity is relatively low (50 to 60 percent). Nucleic acid amplification tests (NAATs) and
molecular probe assays such as Affirm VPIII are currently considered the most sensitive and
specific diagnostic standards for detecting Trichomonas vaginalis.
4. A 42-year-old G3P3003 reports progressive, debilitating dysmenorrhea and heavy
menstrual bleeding lasting 8 days over the past year. Bimanual examination reveals a
symmetrically enlarged, globular, boggy, and moderately tender uterus. She desires uterine
preservation. What is the most likely underlying diagnosis?
A. Endometrial hyperplasia without atypia
B. Adenomyosis
C. Submucosal uterine leiomyomas
D. Chronic pelvic inflammatory disease
Rationale: Adenomyosis is characterized by the benign invasion of endometrial glands and
stroma deep into the myometrium, leading to a uniformly enlarged, boggy, and tender uterus
accompanied by heavy, painful menses. Leiomyomas (fibroids) typically present with an
irregularly enlarged, asymmetric contour rather than a smooth, symmetric, globular
enlargement.
5. A 56-year-old postmenopausal woman presents with a complaint of moderate
vulvovaginal dryness, burning, dyspareunia, and urinary urgency that has worsened over
the past 14 months since her last menstrual period. Physical examination demonstrates
pale, thin, friable vaginal mucosa with loss of rugae and fusion of the labia minora. What is
the most effective first-line medical therapy for this patient's primary condition?
A. Oral conjugated equine estrogen systemic therapy
B. Low-dose vaginal estrogen therapy (cream, tablet, or ring)
C. Systemic selective estrogen receptor modulators (SERMs)
D. High-dose oral medroxyprogesterone acetate therapy
Rationale: Genitourinary syndrome of menopause (GSM) is caused by estrogen deprivation
affecting the vulva, vagina, urethra, and bladder. Low-dose vaginal estrogen therapy provides
localized relief of symptoms with minimal systemic absorption, making it the most effective
first-line therapy for women without systemic vasomotor symptoms.
, 6. A 25-year-old nulliparous woman requests emergency contraception after experiencing a
contraceptive barrier failure (condom breakage) approximately 18 hours ago. Her body
mass index (BMI) is 34 kg/m2. Which emergency contraceptive option is the most effective
for this patient?
A. Single-dose oral levonorgestrel 1.5 mg tablet
B. Copper intrauterine device (Cu-IUD) insertion or oral ulipristal acetate
C. Combined oral contraceptive pills using the Yuzpe regimen
D. High-dose oral medroxyprogesterone acetate injection
Rationale: Levonorgestrel-based emergency contraception (Plan B) has significantly reduced
efficacy in women with a BMI over 26 kg/m2 or weight over 75 kg. Ulipristal acetate
maintains efficacy up to 88 kg, and the copper intrauterine device is highly effective regardless
of patient weight when inserted within five days of unprotected intercourse.
7. A 19-year-old female presents with lower abdominal pain and purulent cervical
discharge. Nucleic acid amplification testing (NAAT) confirms Chlamydia trachomatis
infection. In addition to treating the patient with single-dose azithromycin or doxycycline,
what critical partner management step must the clinician take?
A. Advise the patient to have partners tested only if they develop painful scrotal swelling
B. Provide expedited partner therapy (EPT) or prescriptions/referrals for all sexual partners
within the preceding 60 days
C. Require partners to obtain a mandatory pelvic ultrasound prior to receiving antibiotics
D. Instruct the patient to abstain from sexual activity for exactly 14 days post-treatment without notifying
partners
Rationale: CDC guidelines recommend treating all sexual partners within the last 60 days of a
patient diagnosed with a sexually transmitted infection like chlamydia to prevent reinfection
and community spread. Expedited partner therapy (EPT) allows clinicians to provide
medications or prescriptions directly to the patient to take to their partner without a formal
clinical evaluation, where legally permitted.
8. A 48-year-old G2P2002 presents with complaints of unpredictable menstrual cycle
intervals ranging from 22 to 45 days, accompanied by night sweats and hot flashes over the
past eight months. Her serum follicle-stimulating hormone (FSH) level is elevated at 42
IU/L. How is this clinical stage of reproductive aging classified according to STRAW+10
criteria?
A. Premenopause
B. Early menopausal transition (Stage -2)
C. Late menopausal transition (Stage -1)
D. Postmenopause (Stage +1a)
Rationale: The STRAW+10 staging system defines the late menopausal transition (Stage -1) by
persistent differences in cycle length of 7 days or more (e.g., skipped cycles or an interval of
amenorrhea of 60 days or longer). Serum FSH levels fluctuate widely during this phase and
are not diagnostic on their own, but the clinical bleeding pattern establishes the stage.
